Want to see AU:CYP full AI Analyst Report?

Cynata Therapeutics Limited (CYP) Price & Analysis

11 Followers

CYP Stock Chart & Stats

AU$0.29

-AU$0.01(-4.17%)

At close: Jan 09 4:00 PM EST

AU$0.29

-AU$0.01(-4.17%)

Day’s Range― - ―

52-Week RangeAU$0.01 - AU$0.44

Previous CloseN/A

Volume63.41K

Average Volume (3M)233.82K

Market Cap

AU$3.65M

Enterprise ValueAU$60.71M

Total Cash (Recent Filing)AU$2.59M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.98

Next Earnings

Aug 31, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding243,454,380

10 Day Avg. Volume170,513

30 Day Avg. Volume233,823

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)5.14

Price to Sales (P/S)16.31

P/FCF Ratio-3.51

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.03

Revenue Forecast (FY)AU$19.90M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero debt materially reduces financial distress risk and preserves flexibility to fund clinical programs via equity, partnerships, or non-dilutive sources. For a pre-commercial biotech this durable conservatism lengthens runway options and lowers insolvency risk while advancing long-term R&D.

Scalable Allogeneic PlatformAn off-the-shelf iPSC-derived MSC platform is a structural advantage: manufacturing consistency and scale reduce batch variability, lower per-dose costs over time, and create higher barriers to entry. This supports durable partnership, licensing, and commercial opportunities if clinical success is achieved.

High Gross Margins On Product RevenueNear-100% gross margins indicate low direct COGS for the company’s biologic products, implying that incremental revenues can flow to the bottom line once fixed R&D and SG&A absorption improves. Structurally favorable product economics aid long-term profitability scalability.

Bears Say

Sustained Cash BurnPersistent negative operating and free cash flows mean the company relies on external financing to fund trials and operations. Over months, this drives dilution risk and conditionality on capital markets or partners, constraining strategic autonomy and increasing execution risk for long-term programs.

Large, Persistent Operating LossesVery deep negative margins reflect a cost structure far exceeding current revenues, indicating the business is structurally pre-profit and will need sustained successful clinical outcomes and scale to approach breakeven. This lengthens the path to profitability and raises execution and funding risk.

Eroding Equity And AssetsMaterial declines in equity and total assets signal balance-sheet erosion from sustained losses, reducing financial buffers. Over a multi-month horizon this weakens bargaining power with partners and lenders, increases probability of dilutive raises, and limits capital available for advancing programs.

Cynata Therapeutics Limited News

Cynata Options Lapse Clarifies Future Equity Structure

Cynata Therapeutics Limited ( ($AU:CYP) ) has shared an announcement. Cynata Therapeutics Limited has notified the market of...

7d ago

Cynata Discloses Final Director Interest as Dr Darryl Maher Departs Board

Cynata Therapeutics Limited ( ($AU:CYP) ) has issued an announcement. Cynata Therapeutics Limited has announced the cessation of...

11d ago

Cynata Slashes Costs, Axes Staff and Taps R&D Loan to Extend Cash Runway

Cynata Therapeutics Limited ( ($AU:CYP) ) has issued an announcement. Cynata Therapeutics has implemented sweeping cost-cutting measures, making...

11d ago

Major Shareholder FIL Limited Exits Position in Cynata Therapeutics

Cynata Therapeutics Limited ( ($AU:CYP) ) has issued an announcement. Cynata Therapeutics has received notice that FIL Limited...

15d ago

Bioscience Fund Exits Substantial Holding in Cynata Therapeutics

An update from Cynata Therapeutics Limited ( ($AU:CYP) ) is now available. Phillip Asset Management, acting for Bioscience...

24d ago

Cynata to Host Investor Webinar on Results Update

Cynata Therapeutics Limited ( ($AU:CYP) ) has shared an update. Cynata Therapeutics has scheduled an investor webinar for...

25d ago

Cynata’s CYP-004 Fails to Outperform Placebo in Phase 3 Knee Osteoarthritis Trial

Cynata Therapeutics Limited ( ($AU:CYP) ) has issued an update. Cynata Therapeutics reported top-line results from the University...

28d ago

Cynata Halts CYP-001 GvHD Trial After Phase 2 Misses Efficacy Goals

An update from Cynata Therapeutics Limited ( ($AU:CYP) ) is now available. Cynata Therapeutics reported primary evaluation results...

1M ago

Cynata Seeks ASX Trading Suspension Ahead of Key Clinical Trial Results

Cynata Therapeutics Limited ( ($AU:CYP) ) has issued an update. Cynata Therapeutics has requested a voluntary suspension of...

1M ago

Cynata Sets June–July Timeline for Pivotal Stem Cell Trial Readouts

Cynata Therapeutics Limited ( ($AU:CYP) ) has issued an announcement. Cynata Therapeutics has provided an update on the...

2M ago

CYP FAQ

What was Cynata Therapeutics Limited’s price range in the past 12 months?

Cynata Therapeutics Limited lowest share price was AU$0.01 and its highest was AU$0.43 in the past 12 months.

What is Cynata Therapeutics Limited’s market cap?

Cynata Therapeutics Limited’s market cap is AU$3.65M.

When is Cynata Therapeutics Limited’s upcoming earnings report date?

Cynata Therapeutics Limited’s upcoming earnings report date is Aug 31, 2026 which is in 45 days.

How were Cynata Therapeutics Limited’s earnings last quarter?

Cynata Therapeutics Limited released its earnings results on Feb 26, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.

Is Cynata Therapeutics Limited overvalued?

According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cynata Therapeutics Limited pay dividends?

Cynata Therapeutics Limited does not currently pay dividends.

What is Cynata Therapeutics Limited’s EPS estimate?

Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cynata Therapeutics Limited have?

Cynata Therapeutics Limited has 243,454,380 shares outstanding.

What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?

Cynata Therapeutics Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.054%.

Which hedge fund is a major shareholder of Cynata Therapeutics Limited?

Currently, no hedge funds are holding shares in AU:CYP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cynata Therapeutics Limited Stock Smart Score

Underperform

Fundamentals

Return on Equity

-179.37%

Trailing 12-Months

Asset Growth

-62.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cynata Therapeutics Limited

Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully concluded Phase I clinical trials for graft versus host disease. The company's pipeline also includes CYP-004, currently in Phase III trials for osteoarthritis treatment, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. Furthermore, Cynata is advancing therapies for a broad spectrum of conditions such as asthma, heart attacks, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata maintains a crucial strategic alliance with Fujifilm, which is responsible for the clinical and commercial manufacturing and supply of its Cymerus therapeutic mesenchymal stem cell products.